Scleroderma: From Pathogenesis to Comprehensive Management

ISBN-13: 9781461490272 / Angielski / Miękka / 2013 / 689 str.

Varga

Opis

This essential resource presents the most up-to-date information on scleroderma. A clear and concise synthesis of current concepts in pathogenesis and modern approaches to management, this book is comprised of the authoritative work of international experts. With an integrated multidisciplinary approach to comprehensive care, this book iseasily accessible for health care professionals in many fields. It is a valuable resource for rheumatologists, pulmonologists, cardiologists, gastroenterologists, nephrologists and all those involved in the care of scleroderma patients."

Recenzje

From the reviews:

"This is a very comprehensive summary of the various aspects of scleroderma, one of the most complex and challenging autoimmune disorders to diagnose and treat. ... a valuable resource not only for practicing rheumatologists, but also for any physicians who treat scleroderma patients, including gastroenterologists, nephrologists, primary care doctors, and residents. ... good number of illustrations and graphs make the subject more interesting and easier to comprehend. ... The authors have done an incredible job summarizing all the recent research and advances in this area." (Saba Beg, Doody's Book Reviews, January, 2014)

"Scleroderma: From Pathogenesis to Comprehensive Management emphasises the multidisciplinary approach to comprehensive care of the scleroderma patient. The book serves as a valuable management guide and scientific review for both the 'sclerodermaologist'/clinician and the budding researcher seeking in-depth and authoritative discussions on all aspects of scleroderma. The book is recommended to any clinician who participates in the care of our patients with this complex, yet fascinating syndrome." (R. Saggar, European Respiratory Review, Vol. 21 (126), December, 2012)
"This book integrates the latest developments in scleroderma in terms of understanding its pathophysiology and management. The purpose is to provide an ultimate source that integrates historical management, current pathophysiology, and the possible future of better therapy. ... The book is written for rheumatologists." (Hyon Ju Park, Doody's Review Service, March, 2012)

Spis treści

Foreword       Stephen Katz MD, PhD, Director, NIAMS

Foreword       A personal view: Luke Evnin, PhD, President, SRF

Preface           John Varga, MD, Christopher P. Denton, PhD, FRCP, Fredrick M. Wigley, MD

Section I. Introduction

Chapter 1 – Historical Perspective – Christopher P. Denton, PhD, FRCP, and Carol Black

Chapter 2 - Therapeutic evolution: a professor’s view – Frank A. Wollheim, MD, PhD, FRCP                  

Section II: Epidemiology, Genetics and Classification

Chapter 3 – Overview: Epidemiology, Genetics and Classification – Christopher P. Denton, PhD, FRCP

Chapter 4 – Epidemiology and Environmental Risk Factors – Jammie K. Barnes, MD,

and Maureen D. Mayes, MD, MPH

Chapter 5  – Genetic Factors – Yannick Allanore, MD, PhD, and Filemon K. Tan, MD, PhD

Chapter 6 – Disease Subsets in Clinical Practice  – Robyn Therese Domsic, MD, MPH,

and Thomas A. Medsger, Jr., MD

Chapter 7 – Evolving Concepts of Diagnosis and Classification – Lorinda Chung, MD, MS, Jaap Fransen, MD, and Frank H.J. Van den Hoogen, MD, PhD

Chapter 8 – Disease Classification using Molecular Signatures  – Michael L. Whitfield, PhD, and Robert Lafyatis, MD

Section III: Scleroderma in Children

Chapter 9 – Juvenile Localized Scleroderma – Francesco Zulian, MD

Chapter 10 - Juvenile Systemic Scleroderma - Ivan Foeldvari, MD

Section IV:  Other Fibrosing Skin Conditions

Chapter 11 – Scleroderma Mimics –Laura K. Hummers, MD, ScM

Chapter 12 - Localized Forms of Scleroderma in Adults – Amy E. Gilliam, MD, and Anita C. Gilliam, MD, PhD

Chapter 13 - Nephrogenic Systemic Fibrosis – Peter J. Wermuth, PhD, and Sergio A. Jimenez, MD

Section V: Pathogenetic Basis

Chapter 14 - Overview: Integrated Pathogenesis – John Varga, MD

Chapter 15 - Immunological Mechanisms – Francisco Boin, MD, and Carlo Chizzolini, MD

Chapter 16 - Innate Immunity – Keith B. Elkon, MD, and Julia J. Rhiannon, MD, MSW

Chapter 17 – Autoantibodies in Pathogenesis – Kimberly Doering, BS, and Antony Rosen, MB ChB, BSc (Hons)

Chapter 18 - The Clinical Aspects of Autoantibodies - John D. Pauling, BMBS, MRCP, and Neil McHugh, MB, ChB, MD, FRCP, FRCPath

Chapter 19 – Mechanisms of Vascular Disease – Bashar Kalaheh, MD, and Mary Jo Mulligan-Kehoe, PhD

Chapter 20  - Vascular Biomarkers – Laura K. Hummers, MD, ScM

Chapter 21 – Mechanisms of Fibrosis – John Varga, MD

Chapter 22 – Fibrosis: Insights from the stiff skin syndrome – Elizabeth E. Gerber, BS, and Harry C. Dietz, MD

Chapter 23 - Biomarkers of Fibrosis – Christian Beyer, MD, Oliver Distler, MD, and Jörg H.W. Distler, MD

Chapter 24 – Overview of Animal Models – Christopher P. Denton, PhD, FRCP, and Robert Lafyatis, MD

Section

VI: Cardiovascular Manifestations and Management

Chapter 25 – Overview: Cardiovascular Manifestations and Management – Fredrick M. Wigley, MD

Chapter 26 – Raynaud Phenomenon  – Arianne Herrick and Fredrick M. Wigley, MD

Chapter 27 – Nailfold Capillaroscopy – Maurizio Cutolo, MD and Vanessa Smith, MD, PhD

28SystemicVascular Disease , MD, PhD, MD, FRCP

Chapter 29 – Scleroderma Renal Crisis – Christopher P. Denton, PhD, FRCP, and Virginia Steen, MD

Chapter 30 – Cardiac Involvement –Sanjiv J. Shah, MD, and André Kahan, MD, PhD

Chapter 31 – Erectile Dysfunction – Edward V. Lally, MD, Arthur L. Burnett, MD, MBA, FACS, and Trinity J. Bivalacqua, MD, PhD

Section VII: Pulmonary manifestations and management

Chapter 32 – Overview: Pulmonary manifestations and management – Christopher P. Denton, PhD, FRCP

Chapter 33 – Clinical Assessment of Lung Disease – Greg J. Keir, MBBS, FRACP, Richard M. Silver, MD, and Athol U. Wells, MD, FRCP

Chapter 34 – Computerized Tomography of Interstitial Lung Disease – Athol U. Wells, MD, FRCP, and Jonathan Goldin MD, PhD, FRCR

Chapter 35 – Treatment of interstitial lung disease – Dinesh Khanna, MD, MS, and Donald P. Tashkin, MD

Chapter 36 – Clinical Assessment of Pulmonary Hypertension – Harrison W. Farber, MD, Michael York, MD, Eric Hachulla, MD, PhD

Chapter 37 – Treatment of Pulmonary Hypertension –Todd H. Kolb, MD, PhD, and Paul M. Hassoun, MD

Chapter 38 – Complex Challenges of Pulmonary Hypertension – John Gerard

Coghlan, MD, FRCP

Section VIII: Gastrointestinal manifestations and management

Chapter 39– Overview: Gastrointestinal Manifestations and Management - Seth Sweetser, MD, and Michael Camilleri, MD

Chapter 40 – Upper Gastrointestinal Tract - John O. Clarke, MD, and Ikuo Hirano, MD

Chapter 41 – Small and Large Intestinal Involvement - Philip J. Clements, MD, MPH, Terri R. Getzug, MD, and Dinesh Khanna, MD, MS

Section XIX: Skin, musculoskeletal and other complications

Chapter 42 - Evaluation and Management of Skin Disease – Noëlle Starr Sherber, MD, FAAD

Chapter 43 – Skeletal Muscle Involvement – Andrew L. Mammen, MD, PhD

Chapter 44 - Tendons, Joints and Bone – Jérôme Avouac, MD, PhD, and Yannick Allanore, MD, PhD

Chapter 45 – Pregnancy – Virginia Steen, MD, and Eliza F. Chakravarty, MD, MS

Chapter 46 - Overlooked Manifestations– Ami A. Shah, MD, MHS

Section X:  Disease-modifying strategies

Chapter 47 –Principles of ManagementD. , MD, MPH

Chapter 48 - Immunomodulatory Therapies – Jacob M. van Laar, MD, PhD

Chapter 49 - Cell-Based Therapies – Alan G. Tyndall, MD, FRACP, Rheumatology FMH, and Keith M. Sullivan, MD

Chapter 50 - Investigative Approaches to Drug Therapy – Voon H. Ong, PhD, MRCP, and Christopher P. Denton, PhD, FRCP

Chapter 51 – Complementary and alternate medicine approaches – Judy A. Fulop, MD, MS, FABNO, and John Varga, MD

Chapter 52 - Physical and occupational therapy– Luc Mouthon,

MD, PhD, and Janet L. Poole, PhD, OTR/L

Chapter 53 – Evaluation and Management of Psychosocial Issues – El-Baalbaki Ghassan, PhD, Lisa Jewett, BA, MSc, Jennifer A. Haythornthwaite, PhD, and Brett D. Thombs, PhD

Section XI: Outcome assessment

Chapter 54 - Issues in Clinical Trial Design– Suzanne Kafaja, MD, Daniel E. Furst, MD, and Janet E. Pope, MD, MPH, FRCPC

Chapter 55 - Measuring Disease Activity– Dinesh Khanna, MD, MS

Chapter 56 – Patient Reported Outcomes – Monique Hinchcliff, MD, and David Cella, PhD